Total medical devices industry cross border deals worth $4.6bn were announced globally for July 2021, with the $1.21bn private equity deal with Lifebrain being the sector’s biggest investment, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 87.9% over the previous month of $38bn and a drop of 28.4% when compared with the last 12-month average of $6.41bn.
In terms of number of cross border deals, the sector saw a rise of 13.95% with 49 deals in July 2021 when compared to the last 12-month average of 43 deals.
In value terms, Europe led the activity with cross border deals worth $2.69bn in July 2021.
medical devices industry cross border deals in July 2021: Top deals
The top five cross border deals accounted for 69.7% of the overall value during July 2021.
The combined value of the top five cross border deals stood at $3.2bn, against the overall value of $4.6bn recorded for the month.
The top five medical devices industry cross border deals of July 2021 tracked by GlobalData were:
1) Lifebrain $1.21bn private equity deal with EQT Partners
2) The $1.17bn acquisition of Vectura Group by Philip Morris International
3) Simbionix USA $305m acquisition deal with Surgical Science Sweden
4) The $250m private equity of Certara USA by Mubadala Investment
5) Imperative Care $260m venture financing deal with Ally Bridge Group,AMED Ventures GP,Ascension Health Ventures,Bain Capital Life Sciences,D1 Capital Partners,Delos Capital,HealthCor Management,Innovatus Capital Partners and Rock Springs Capital Management